IM Cannabis Return on Equity

IM Cannabis (IMCC) currently reports a ROE of 314.01%. That is above the Healthcare sector average of 21.67%. Use the charts on this page to explore IM Cannabis's ROE history and peer comparisons.

IM Cannabis's ROE of 314.01% is higher than the Healthcare sector average of 21.67%. That is roughly 1349.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but IM Cannabis's current 314.01% should be judged against Healthcare norms (sector average: 21.67%) and against IMCC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 314.01%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for IM Cannabis, and consider following IMCC for alerts when major investors trade the stock.

IM Cannabis is classified in the Healthcare sector. On ROE, it currently shows 314.01% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMCC with unrelated industries.